Aprea Therapeutics, Inc. (APRE)

Import this data to Google Sheets with:

=jivedata("APRE","financials")

Full statements spill as a table. For one cell: =jivedata("APRE","Revenue") or =jivedata("APRE","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Aprea Therapeutics, Inc.

APRE • CIK 0001781983

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue Not from Contract with Customer	$583.231	$1,502.581	$285.759	$285.759
Operating Income (Loss)	$-15,471.963	$-14,319.655	$-13,233.836	$-13,223.073
Net Income (Loss) Attributable to Parent	$-14,286.756	$-12,958.711	$-12,599.569	$-12,307.261
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$-14,274.621	$-12,974.817	$-12,606.904	$-12,296.461
Weighted Average Number of Shares Outstanding, Basic	3,617,607	5,509,921	6,538,722	34,691,530
Research and Development Expense (Excluding Acquired in Process Cost)	$7,627.491	$9,363.537	$7,043.035	$6,720.965
General and Administrative Expense	$8,427.703	$6,458.699	$6,476.56	$6,507.293
Operating Expenses	$16,055.194	$15,822.236	$13,519.595	$13,228.258
Interest Income (Expense), Nonoperating, Net	$1,224.133	$1,289.144	$652.086	$763.04
Other Nonoperating Income	—	—	$77.5	$77.5
Foreign Currency Transaction Gain (Loss), before Tax	$-38.926	$71.8	$-95.319	$-3.728
Other Nonoperating Income (Expense)	$1,185.207	$1,360.944	$634.267	$915.812
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	$12.135	$-16.106	$-7.335	$10.8

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Property, Plant and Equipment, Net	$88.362	$81.522	$59.807	$64.033
Restricted Cash, Noncurrent	$40.717	$40.17	$41.186	$41.615
Other Assets, Noncurrent	—	$281.662	$271.162	$271.162
Assets	$22,650.174	$23,979.493	$15,933.401	$42,289.924
Cash and Cash Equivalents, at Carrying Value	$21,606.82	$22,849.885	$14,599.347	$41,233.428
Prepaid Expense and Other Assets, Current	$914.275	$726.254	$961.899	$679.686
Assets, Current	$22,521.095	$23,576.139	$15,561.246	$41,913.114
Accounts Payable, Current	$1,670.369	$1,352.24	$713.668	$935.139
Liabilities, Current	$4,385.605	$3,360.975	$2,764.358	$3,092.302
Common Stock, Value, Issued	$3.736	$5.481	$8.192	$12.391
Additional Paid in Capital	$335,644.204	$350,971.225	$356,709.645	$389,596.149
Accumulated Other Comprehensive Income (Loss), Net of Tax	$-10,611.273	$-10,627.379	$-10,634.714	$-10,617.617
Retained Earnings (Accumulated Deficit)	$-308,083.161	$-321,041.872	$-333,641.441	$-340,520.662
Stockholders' Equity Attributable to Parent	$16,953.506	$19,307.455	$12,441.682	$38,470.261
Common Stock, Shares Authorized	400,000,000	400,000,000	400,000,000	400,000,000
Common Stock, Shares, Issued	3,736,673	5,481,055	8,192,538	12,391,136

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-14,286.756	$-12,958.711	$-12,599.569	$-12,307.261
Net Cash Provided by (Used in) Operating Activities	$-12,177.608	$-13,556.718	$-12,894.439	$-12,168.011
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect	$-7,130.711	$1,249.699	$-8,254.201	$27,188.536
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$-8.399	$-7.181	$4.679	$-0.37
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$21,647.537	$22,890.055	$14,640.533	$41,832.002
Depreciation, Depletion and Amortization	$7.052	$22.318	$21.715	$22.032
Payments to Acquire Property, Plant, and Equipment	$93.093	$15.478	$15.478	—
Employee Benefit and Share-based Payment Arrangement, Noncash	$444.459	$489.436	$478.141	$427.039
Net Cash Provided by (Used in) Investing Activities	$-93.093	$-15.478	$-15.478	—
Foreign Currency Transaction Gain (Loss), before Tax	$-38.926	$71.8	$-95.319	$-3.728
Proceeds from Warrant Exercises	—	—	$0.091	$0.091
Proceeds from Issuance of Common Stock	$5,788.918	$16,140.356	$5,047.606	$40,187.468
Payments of Stock Issuance Costs	$648.928	$1,318.461	$407.459	$3,301.607
Net Cash Provided by (Used in) Financing Activities	$5,139.99	$14,821.895	$4,640.238	$36,885.952
Cash and Cash Equivalents, at Carrying Value	$21,606.82	$22,849.885	$14,599.347	$41,789.828
Restricted Cash	$40.717	$40.17	$41.186	$42.174
Conversion of Stock, Amount Issued	—	—	$583.702	$583.702
Increase (Decrease) in Prepaid Expense and Other Assets	$-451.994	$96.674	$217.906	$285.123
Increase (Decrease) in Accounts Payable	$827.463	$-314.207	$-646.701	$-262.771
Increase (Decrease) in Accrued Liabilities	$-189.72	$-115.541	$-64.488	$195.295
Increase (Decrease) in Deferred Revenue	$528.974	$-528.974	$-528.974	$-528.974

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("APRE","financials")

Full statements spill as a table. For one cell: =jivedata("APRE","Revenue") or =jivedata("APRE","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.